Biotech Calendar: Key Dates for December

BOSTON, Mass. ( TheStreet) -- The year is coming to an end but the biotech calendar is still buzzing with important, stock-moving events right up to New Year's Eve.

Before I get to the calendar, I want to mention some key December biotech catalysts without a fixed date but which investors should still be keeping in mind.

Delcath Systems ( DCTH) is supposed to complete the U.S. approval application for its liver tumor Chemosaturation System before the end of the month. RXi Pharmaceuticals ( RXII) has promised investors a significant drug development partnership before year's end. Investors will also be eager to hear the outcome of the December meeting between Arena Pharmaceuticals ( ARNA) and FDA following the latter's rejection of Arena's obesity drug lorcaserin.

Cell Therapeutics ( CTIC) is expecting a ruling on its appeal of the FDA's rejection of the company's lymphoma drug pixantrone. Amgen ( AMGN) will announce results from a phase III trial investigating whether treatment with Xgeva can prevent the spread of prostate cancer to the bone. Incyte Pharmaceuticals ( INCY) is expected to announce top-line results from a U.S. phase III study of INCB18424 in myelofibrosis.

Celgene ( CELG) could have data from two important, phase III clinical trials before the books close on 2010: A phase III study of Abraxane in front-line non-small cell lung cancer and a phase III study of Amrubicin in small-cell lung cancer (although this latter study may not be completed until early 2011.)

Corcept Therapeutics ( CORT) will announce top-line results from a phase III study of Corlux in Cushing's Syndrome during December.

Now, to the December biotech calendar:

Dec. 2:

Affymax ( AFFY) provides an update on regulatory plans for the experimental anemia dru Hematide.

Exelixis ( EXEL) investor/analyst meeting.

Targacept ( TRGT) investor/analyst meeting.

Dec. 3:

Orexigen Therapeutics ( OREX): FDA should release review documents on the obesity drug Contrave in advance of the advisory panel meeting.

Dec. 4-7:

American Society of Hematology annual meeting: Important data presentations from Onyx Pharmaceuticals ( ONXX), Seattle Genetics ( SGEN), Celgene, and others.

Dec. 5-9:

American College of Neuropsychopharmacology (ACNP) annual meeting.

Dec. 7:

Orexigen Therapeutics: FDA advisory panel reviewing the obesity drug Contrave. I'll be live-blogging the Contrave panel, sign up below for an email reminder.

Dec. 8-12:

San Antonio Breast Cancer Symposium

Dec. 9:

FDA approval decision for Human Genome Sciences' ( HGSI) lupus drug Benlysta.

Dec. 14:

Onyx Pharmaceuticals investor/analyst meeting.

Dec. 16:

FDA approval decision for AstraZeneca's ( AZN) blood thinner Brilinta.

Dec. 29:

FDA approval decision for Alimera Sciences' ( ALIM) Iluvien for treatment of diabetic macular edema.

FDA approval decision for MannKind's ( MNKD) inhaled insuline device Afrezza

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes